Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(18):1351-1352; doi:10.1093/jnci/djg070
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by George, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by George, S. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 Oxford University Press

EDITORIAL

Selection Bias, Phase II Trials, and the FDA Accelerated Approval Process

Stephen L. George

Correspondence to: Stephen L. George, PhD, Duke University Medical Center, Cancer Center Biostatistics, Box 3958, Durham NC 27710 (e-mail: stephen.george@duke.edu).

The first 10% of the full text of this article appears below.

Several observational studies have found that the distance traveled from a patient’s home to the treatment center is an important prognostic variable. In this issue of the Journal, Lamont et al. (1) investigated this phenomenon for clinical trials at a specialized cancer treatment center and reported that patients with head and neck cancer enrolled on phase II clinical trials experienced better survival the further they lived from the treatment center. This finding could not be explained away by adjustment for other observable demographic, medical, or socioeconomic factors (e.g., age, stage of disease, performance status, income level) that are known to influence outcomes. We are . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
J. K. Chan, S. M. Ueda, V. E. Sugiyama, C. D. Stave, J. Y. Shin, B. J. Monk, B. I. Sikic, K. Osann, and D. S. Kapp
Analysis of Phase II Studies on Targeted Agents and Subsequent Phase III Trials: What Are the Predictors for Success?
J. Clin. Oncol., March 20, 2008; 26(9): 1511 - 1518.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. Sorbye, C.-H. Kohne, D. J. Sargent, and B. Glimelius
Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: A proposal for standardization of patient characteristic reporting and stratification
Ann. Onc., October 1, 2007; 18(10): 1666 - 1672.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. I. Zia, L. L. Siu, G. R. Pond, and E. X. Chen
Comparison of Outcomes of Phase II Studies and Subsequent Randomized Control Studies Using Identical Chemotherapeutic Regimens
J. Clin. Oncol., October 1, 2005; 23(28): 6982 - 6991.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
A. Munoz and J. Samet
Re: Is Patient Travel Distance Associated With Survival on Phase II Clinical Trials in Oncology?
J Natl Cancer Inst, March 3, 2004; 96(5): 411 - 411.
[Full Text] [PDF]